## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($188.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Does Becton Dickinson’s Recent Slide Create an Opportunity for Long Term Investors in 2025?**
- Source: Simply Wall Street | 20251222T200812 | Bullish | Relevance: 100%
- Becton Dickinson (NYSE: BDX) has seen its stock slide recently but may present a value opportunity for long-term investors. A Discounted Cash Flow analysis suggests the stock is currently undervalued by 39.7%, trading at a significant discount to its estimated fair value. While its Price to Earnings ratio is slightly above the industry average, the company's fundamentals, including its focus on higher-margin medical technologies and integration of acquisitions, indicate it's reasonably valued on earnings.

**2. BD and Penn Institute Ink Collaboration to Advance Immunotherapy**
- Source: The Globe and Mail | 20251222T190827 | Bullish | Relevance: 100%
- Becton, Dickinson and Company (BDX) has announced a collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to advance immunotherapy. Their partnership will focus on developing a high-parameter flow cytometry panel and conducting a study involving 1,000 people to understand the human immune system and support immune-mediated treatments. This initiative aims to translate complex immune data into actionable information for clinical care, strengthening BD's position in advanced flow cytometry and single-cell analysis.

**3. Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly**
- Source: Reuters | 20251222T210811 | Bearish | Relevance: 100%
- Becton Dickinson, a medical device manufacturer, is being sued by rival Tela Bio Inc. for allegedly creating a monopoly in the U.S. surgical hernia mesh market, leading to higher prices for patients and healthcare providers. Tela Bio claims Becton Dickinson leveraged its market dominance to exclude competitors and punish hospitals for purchasing other products, seeking unspecified damages and a court order to promote competition. This new lawsuit follows Becton Dickinson's settlement of approximately 38,000 personal injury lawsuits related to its hernia mesh products last year.

**4. Does Becton Dickinson’s Recent Slide Create an Opportunity for Long Term Investors in 2025?**
- Source: Simply Wall Street | 20251222T202011 | Bullish | Relevance: 100%
- Becton Dickinson (NYSE: BDX) has seen its stock price decline, leading some to question if it presents a value opportunity. A Discounted Cash Flow (DCF) analysis suggests it is undervalued by 39.7%, with an estimated intrinsic value of $324.56 per share compared to its current price of $195.59. However, its Price-to-Earnings (PE) ratio of 33.2x is slightly above the industry average, indicating it is reasonably valued based on current earnings.

**5. L. Roy Papp & Associates LLP Has $910,000 Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251220T121345 | Neutral | Relevance: 100%
- L. Roy Papp & Associates LLP significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 59% in Q3, now holding shares valued at $910,000. Despite this, other institutional investors have increased their positions in the medical instruments supplier. Market analysts maintain a "Hold" rating for BDX with a consensus price target of $205.64, and the company recently raised its quarterly dividend to $1.05 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.2B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.4 |
| Current P/E | 13.2 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.9% to -0.7% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.72% (CS: 38) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | -0.19 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.038x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $196.75
- **Stop Loss:** $188.93 (4.0% risk)
- **Target:** $204.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $30,102.75
- **Portfolio %:** 30.10%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*